JP2021521266A5 - - Google Patents
Info
- Publication number
- JP2021521266A5 JP2021521266A5 JP2020569776A JP2020569776A JP2021521266A5 JP 2021521266 A5 JP2021521266 A5 JP 2021521266A5 JP 2020569776 A JP2020569776 A JP 2020569776A JP 2020569776 A JP2020569776 A JP 2020569776A JP 2021521266 A5 JP2021521266 A5 JP 2021521266A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- independently selected
- compound according
- groups
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862670323P | 2018-05-11 | 2018-05-11 | |
| US62/670,323 | 2018-05-11 | ||
| PCT/US2019/032043 WO2019217972A1 (en) | 2018-05-11 | 2019-05-13 | Kdm1a inhibitors for the treatment of disease |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021521266A JP2021521266A (ja) | 2021-08-26 |
| JP2021521266A5 true JP2021521266A5 (enExample) | 2022-05-16 |
| JP7450559B2 JP7450559B2 (ja) | 2024-03-15 |
Family
ID=68468431
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020569776A Active JP7450559B2 (ja) | 2018-05-11 | 2019-05-13 | 疾患の処置のためのｋｄｍ１ａ阻害剤 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11578059B2 (enExample) |
| EP (1) | EP3790867B1 (enExample) |
| JP (1) | JP7450559B2 (enExample) |
| KR (1) | KR102684364B1 (enExample) |
| CN (1) | CN112513020B (enExample) |
| AU (1) | AU2019265022B2 (enExample) |
| BR (1) | BR112021001066A2 (enExample) |
| CA (1) | CA3103392A1 (enExample) |
| ES (1) | ES2977656T3 (enExample) |
| IL (1) | IL279260B2 (enExample) |
| PH (1) | PH12020552135A1 (enExample) |
| SG (1) | SG11202012289UA (enExample) |
| WO (1) | WO2019217972A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6521967B2 (ja) | 2013-08-06 | 2019-05-29 | イマーゴ バイオサイエンシーズ インコーポレイテッド | 疾患の治療のためのｋｄｍ１ａ阻害剤 |
| JP6727216B2 (ja) | 2015-02-12 | 2020-07-22 | イマーゴ バイオサイエンシーズ インコーポレイテッド | 疾患の治療のためのｋｄｍ１ａ阻害剤 |
| CN111194306B (zh) | 2016-08-16 | 2023-05-16 | 伊美格生物科学公司 | 用于制备kdm1a抑制剂的方法和过程 |
| JP7450559B2 (ja) | 2018-05-11 | 2024-03-15 | イマーゴ バイオサイエンシーズ インコーポレイテッド | 疾患の処置のためのｋｄｍ１ａ阻害剤 |
| MX2022007113A (es) * | 2019-12-09 | 2022-07-11 | Imago Biosciences Inc | Inhibidores de la desmetilasa de la histona especifica de la lisina para el tratamiento de las neoplasias mieloproliferativas. |
| US20240216357A1 (en) * | 2021-03-24 | 2024-07-04 | Sichuan Huiyu Pharmaceutical Co., Ltd. | Polycyclic compound and application thereof |
| CN114591324B (zh) * | 2021-03-30 | 2023-05-05 | 深圳微芯生物科技股份有限公司 | 一类吡嗪酮衍生物、其制备及其应用 |
| CA3231846A1 (en) | 2021-04-08 | 2022-10-13 | Tamara Maes | Combinations of lsd1 inhibitors for treating myeloid cancers |
| US20250295660A1 (en) | 2022-05-09 | 2025-09-25 | Oryzon Genomics, S.A. | Methods of treating nf1-mutant tumors using lsd1 inhibitors |
| US20250275969A1 (en) | 2022-05-09 | 2025-09-04 | Oryzon Genomics, S.A. | Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors |
| US20260151399A1 (en) | 2022-11-24 | 2026-06-04 | Oryzon Genomics, S.A. | Combinations of lsd1 inhibitors and menin inhibitors for treating cancer |
| US20260085082A1 (en) * | 2022-12-23 | 2026-03-26 | Imago Biosciences, Inc. | Kdm1a inhibitors for the treatment of disease |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005289517A1 (en) | 2004-09-24 | 2006-04-06 | Centre National De La Recherche Scientifique | Methods and compositions for treating flaviviruses, pestiviruses and hepacivirus |
| CA2676173A1 (en) * | 2007-02-16 | 2008-08-28 | Amgen Inc. | Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors |
| UA98961C2 (uk) * | 2007-06-27 | 2012-07-10 | Астразенека Аб | Похідні піразинону та їх застосування у лікуванні легеневих захворювань |
| KR101586503B1 (ko) | 2007-09-13 | 2016-01-18 | 코덱시스, 인코포레이티드 | 아세토페논의 환원을 위한 케토리덕타제 폴리펩티드 |
| HUE027683T2 (en) | 2007-10-01 | 2016-10-28 | Codexis Inc | Ketoreductase polypeptides for the production of azetidinone |
| WO2010025287A2 (en) | 2008-08-27 | 2010-03-04 | Codexis, Inc. | Ketoreductase polypeptides for the production of 3-aryl-3-hydroxypropanamine from a 3-aryl-3-ketopropanamine |
| EP2177502A1 (en) | 2008-10-17 | 2010-04-21 | Oryzon Genomics, S.A. | Compounds and their use |
| WO2010043721A1 (en) | 2008-10-17 | 2010-04-22 | Oryzon Genomics, S.A. | Oxidase inhibitors and their use |
| JPWO2010143582A1 (ja) | 2009-06-11 | 2012-11-22 | 公立大学法人名古屋市立大学 | フェニルシクロプロピルアミン誘導体及びｌｓｄ１阻害剤 |
| US8415381B2 (en) * | 2009-07-30 | 2013-04-09 | Novartis Ag | Heteroaryl compounds and their uses |
| WO2011035941A1 (en) | 2009-09-25 | 2011-03-31 | Oryzon Genomics S.A. | Lysine specific demethylase-1 inhibitors and their use |
| US8946296B2 (en) | 2009-10-09 | 2015-02-03 | Oryzon Genomics S.A. | Substituted heteroaryl- and aryl-cyclopropylamine acetamides and their use |
| RS55348B1 (sr) | 2010-04-19 | 2017-03-31 | Oryzon Gnomics S A | Inhibitori lizin specifične demetilaze-1 i njihova upotreba |
| US8765820B2 (en) | 2010-04-20 | 2014-07-01 | Universita Degli Studi Di Roma “La Sapienza” | Tranylcypromine derivatives as inhibitors of histone demethylases LSD1 and/or LSD2 |
| EP2598480B1 (en) | 2010-07-29 | 2019-04-24 | Oryzon Genomics, S.A. | Cyclopropylamine derivatives useful as lsd1 inhibitors |
| DK2598482T3 (en) * | 2010-07-29 | 2018-06-14 | Oryzon Genomics Sa | ARYLCYCLOPROPYLAMINE-BASED DEMETHYLASE INHIBITORS OF LSD1 AND THEIR MEDICAL USE |
| WO2012034116A2 (en) | 2010-09-10 | 2012-03-15 | The Johns Hopkins University | Small molecules as epigenetic modulators of lysine-specific demethylase 1 and methods of treating disorders |
| US20120108500A1 (en) | 2010-10-07 | 2012-05-03 | Naoki Sakane | Compositions and Methods for Modulating Immunodeficiency Virus Transcription |
| WO2012045883A1 (en) | 2010-10-08 | 2012-04-12 | Oryzon Genomics S.A. | Cyclopropylamine inhibitors of oxidases |
| WO2012071469A2 (en) | 2010-11-23 | 2012-05-31 | Nevada Cancer Institute | Histone demethylase inhibitors and uses thereof for treatment o f cancer |
| EP2712315B1 (en) | 2011-02-08 | 2021-11-24 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for myeloproliferative disorders |
| US20140163041A1 (en) | 2011-02-08 | 2014-06-12 | Oryzon Genomics S.A. | Lysine demethylase inhibitors for myeloproliferative or lymphoproliferative diseases or disorders |
| MX347913B (es) | 2011-03-25 | 2017-05-17 | Glaxosmithkline Intellectual Property (No 2) Ltd | Ciclopropilaminas como inhibidores de desmetilasa 1 especifica de lisina. |
| BR112014002939A2 (pt) | 2011-08-09 | 2017-03-01 | Takeda Pharmaceuticals Co | composto, medicamento, método para profilaxia ou tratamento de doença, a doença sendo esquizofrenia, alzheimer, parkinson ou huntington, uso do composto, e, método para inibir o lsd1 |
| US9469597B2 (en) | 2011-10-20 | 2016-10-18 | Oryzon Genomics S.A. | (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors |
| AU2012324803B9 (en) | 2011-10-20 | 2017-08-24 | Oryzon Genomics, S.A. | (hetero)aryl cyclopropylamine compounds as LSD1 inhibitors |
| WO2014084298A1 (ja) | 2012-11-28 | 2014-06-05 | 京都府公立大学法人 | リシン構造を有するｌｓｄ1選択的阻害薬 |
| EP2740474A1 (en) * | 2012-12-05 | 2014-06-11 | Instituto Europeo di Oncologia S.r.l. | Cyclopropylamine derivatives useful as inhibitors of histone demethylases kdm1a |
| WO2014164867A1 (en) * | 2013-03-11 | 2014-10-09 | Imago Biosciences | Kdm1a inhibitors for the treatment of disease |
| SG11201510369WA (en) | 2013-06-25 | 2016-01-28 | Univ Canberra | Methods and compositions for modulating cancer stem cells |
| JP6521967B2 (ja) | 2013-08-06 | 2019-05-29 | イマーゴ バイオサイエンシーズ インコーポレイテッド | 疾患の治療のためのｋｄｍ１ａ阻害剤 |
| LT3105218T (lt) | 2014-02-13 | 2019-12-10 | Incyte Corp | Ciklopropilaminai kaip lsd1 inhibitoriai |
| CN121203988A (zh) | 2014-04-22 | 2025-12-26 | C-乐克塔股份有限公司 | 酮还原酶 |
| PL3160956T3 (pl) * | 2014-06-27 | 2020-11-30 | Celgene Quanticel Research, Inc. | Inhibitory demetylazy-1 specyficznej dla lizyny |
| JP6727216B2 (ja) | 2015-02-12 | 2020-07-22 | イマーゴ バイオサイエンシーズ インコーポレイテッド | 疾患の治療のためのｋｄｍ１ａ阻害剤 |
| US10093668B2 (en) * | 2015-10-28 | 2018-10-09 | Northwestern University | Substituted aromatic N-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (Mnk1) and 2 (Mnk2) |
| US20190070172A1 (en) | 2015-11-05 | 2019-03-07 | Imago Biosciences, Inc. | Lysine-specific histone demethylase as a novel therapeutic target in myeloproliferative neoplasms |
| KR102720551B1 (ko) | 2015-12-29 | 2024-10-21 | 미라티 테라퓨틱스, 인크. | Lsd1 억제제 |
| AU2017263361B2 (en) * | 2016-05-09 | 2021-08-05 | Jubilant Epicore LLC | Cyclopropyl-amide compounds as dual LSD1/HDAC inhibitors |
| CN111194306B (zh) * | 2016-08-16 | 2023-05-16 | 伊美格生物科学公司 | 用于制备kdm1a抑制剂的方法和过程 |
| CN110268067A (zh) | 2016-08-16 | 2019-09-20 | 伊美格生物科学公司 | 用于产生立体异构纯的氨基环丙烷的组合物和方法 |
| WO2018106984A1 (en) | 2016-12-09 | 2018-06-14 | Constellation Pharmaceuticals, Inc. | Markers for personalized cancer treatment with lsd1 inhibitors |
| JP7450559B2 (ja) | 2018-05-11 | 2024-03-15 | イマーゴ バイオサイエンシーズ インコーポレイテッド | 疾患の処置のためのｋｄｍ１ａ阻害剤 |
-
2019
- 2019-05-13 JP JP2020569776A patent/JP7450559B2/ja active Active
- 2019-05-13 KR KR1020207035544A patent/KR102684364B1/ko active Active
- 2019-05-13 AU AU2019265022A patent/AU2019265022B2/en active Active
- 2019-05-13 CA CA3103392A patent/CA3103392A1/en active Pending
- 2019-05-13 ES ES19800758T patent/ES2977656T3/es active Active
- 2019-05-13 US US17/054,126 patent/US11578059B2/en active Active
- 2019-05-13 EP EP19800758.5A patent/EP3790867B1/en active Active
- 2019-05-13 CN CN201980046308.0A patent/CN112513020B/zh active Active
- 2019-05-13 BR BR112021001066-1A patent/BR112021001066A2/pt unknown
- 2019-05-13 IL IL279260A patent/IL279260B2/en unknown
- 2019-05-13 WO PCT/US2019/032043 patent/WO2019217972A1/en not_active Ceased
- 2019-05-13 SG SG11202012289UA patent/SG11202012289UA/en unknown
-
2020
- 2020-12-11 PH PH12020552135A patent/PH12020552135A1/en unknown
-
2022
- 2022-12-15 US US18/066,667 patent/US11932629B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111971279B (zh) | 趋化因子受体调节剂及其用途 | |
| RU2768827C2 (ru) | Модуляторы хемокинового рецептора и их применение | |
| ES2841912T3 (es) | Inhibidores de CXCR2 | |
| ES2657839T3 (es) | Compuestos de pirazolopirimidina inhibidores de JAK y métodos | |
| JP7184889B2 (ja) | 統合的ストレス経路の調節剤 | |
| ES2712973T3 (es) | Inhibidores de MDM2 y métodos terapéuticos que usan los mismos | |
| KR20250029954A (ko) | 피리도[4,3-d]피리미딘 화합물 | |
| JP5760010B2 (ja) | １−（５−ｔｅｒｔ−ブチル−２−フェニル−２Ｈ−ピラゾール−３−イル）−３−［２−フルオロ−４−（１−メチル−２−オキソ−２，３−ジヒドロ−１Ｈ−イミダゾ［４，５−Ｂ］ピリジン−７−イルオキシ）−フェニル］−尿素および関連化合物ならびに治療におけるそれらの使用 | |
| ES2910071T3 (es) | Compuestos de aminopirazina diol como inhibidores de PI3K-Y | |
| JP2025114615A (ja) | 治療薬としての細胞毒素のペプチドコンジュゲート | |
| ES2901216T3 (es) | Nuevos inhibidores selectivos de Jak1 y usos de los mismos | |
| EP3996711B1 (en) | Indanes as pd-l1 inhibitors | |
| US20130310334A1 (en) | 7-Deazapurine Modulators of Histone Methyltransferase, and Methods of Use Thereof | |
| JP2021501788A (ja) | 統合的ストレス経路の調節剤 | |
| KR20250100539A (ko) | 피리도[4,3-d]피리미딘 화합물 | |
| ES2715104T3 (es) | Nuevos derivados de pirazolopirimidina como inhibidores de nik | |
| JP2018162256A (ja) | アポトーシス阻害タンパク質（ｉａｐ）のアンタゴニスト | |
| CN111918652A (zh) | 用于治疗eb病毒阳性的癌症的趋化因子受体调节剂 | |
| EA032639B1 (ru) | Гидрохлоридные соли n-(цианометил)-4-(2-(4-морфолинофениламино)пиримидин-4-ил)бензамида | |
| BR112020001949A2 (pt) | composto, composição farmacêutica, e, métodos para tratar um linfoma não hodgkin e para tratar um linfoma ou uma leucemia | |
| RU2016106003A (ru) | Новые изоиндолиновые или изохинолиновые соединения, способ их получения и фармацевтические композиции, содержащие их | |
| US12006320B2 (en) | Heterocyclic derivatives as PI3K inhibitors | |
| ES3032458T3 (en) | Crystalline form of the hydrochloride salt of 2-((1r,4r)-4-((3-(3-(trifluoromethyl)phenyl) imidazo[1,2-b]pyridazin-6-yl)amino)cyclohexyl)propan-2-ol | |
| JP2022539208A (ja) | チロシンキナーゼ非受容体１（ｔｎｋ１）阻害剤およびその使用 | |
| ES2782113T3 (es) | Compuestos de quinolina fusionados como inhibidores de PI3K/mTor |